Is AI the future of personalized hypertension risk assessment, diagnosis, and treatment?

Mul­ti­ple myelo­ma drug Blenrep and Duchenne mus­cu­lar dy­s­tro­phy ther­a­peu­tic Translar­na did not make the Eu­ro­pean Med­i­cines Agency’s cut for full mar­ket­ing au­tho­riza­tion, the agency an­nounced

cTTP is an ultra-rare, life-threatening blood clotting disorder caused by the ADAMTS13 enzyme deficiency. Credit: Kateryna Kon/Shutterstock. The European Commission (EC) has granted approval to